Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4Melanoma 3Urinary Bladder Neoplasms 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Head and Neck Neoplasms 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1B-Cell Malignancies 1Advanced Solid Tumors 1Advanced Solid Malignancies 1

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × urelumab × Clear all
NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
15 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡